Skip to content
  • Home
  • Corporate
    • About us
    • Leadership
    • Corporate Directory
  • Science
    • Drug Design
    • Scientific Publications
    • Patents
    • Alliances and Partners
    • FAQ
  • Pipeline
    • Pipeline
    • LPH-5 (Phase 1)
    • LPH-48 (pre-clinical)
  • Investors
  • News
  • Contact
  • Home
  • Corporate
    • About us
    • Leadership
    • Corporate Directory
  • Science
    • Drug Design
    • Scientific Publications
    • Patents
    • Alliances and Partners
    • FAQ
  • Pipeline
    • Pipeline
    • LPH-5 (Phase 1)
    • LPH-48 (pre-clinical)
  • Investors
  • News
  • Contact

Day: June 3, 2024

Next-generation psychedelics: should new agents skip the trip?

CSO Jesper L. Kristensen comments on the advantageous position of LPH-5 inthe landscape of next generation psychedelics. https://www.nature.com/articles/s41587-024-02285-1

Lophora is developing novel, next-generation, rapid-acting medicines to treat neurological and psychiatric disorders, such as depressive, anxiety, eating, and mood disorders, PTSD, and substance use disorders.

Quick Links
  • About us
  • Pipeline
  • Investors
  • News
  • Contact
  • About us
  • Pipeline
  • Investors
  • News
  • Contact
Get In Touch

Gyldenlundsvej 21, 1
2920 Charlottenlund
Greater Copenhagen Area
Denmark

Company/VAT number: DK39871033

  • Email: contact@lophora.com
  • Phone: +45 51 86 84 82

© 2025 All Rights Reserved.